New York State Common Retirement Fund Kinnate Biopharma Inc. Transaction History

New York State Common Retirement Fund

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	SELL	$2.33 - $6.84 $5,531 - $16,238	-2,374 Reduced 91.87%	210 $1,000
Q1 2023 May 02, 2023	SELL	$3.46 - $7.98 $56,249 - $129,730	-16,257 Reduced 86.29%	2,584 $16,000
Q4 2022 Jan 30, 2023	SELL	$5.26 - $12.19 $215 - $499	-41 Reduced 0.22%	18,841 $115,000
Q3 2022 Nov 08, 2022	BUY	$9.86 - $15.76 $1,015 - $1,623	103 Added 0.55%	18,882 $226,000
Q2 2022 Aug 04, 2022	SELL	$7.43 - $13.0 $185 - $325	-25 Reduced 0.13%	18,779 $237,000
Q1 2022 May 05, 2022	SELL	$7.73 - $17.99 $100 - $233	-13 Reduced 0.07%	18,804 $212,000
Q4 2021 Feb 02, 2022	BUY	$16.5 - $25.48 $136,603 - $210,948	8,279 Added 78.56%	18,817 $333,000
Q3 2021 Nov 02, 2021	SELL	$17.81 - $24.87 $45,825 - $63,990	-2,573 Reduced 19.62%	10,538 $243,000
Q2 2021 Aug 02, 2021	BUY	$22.19 - $31.55 $128,946 - $183,337	5,811 Added 79.6%	13,111 $305,000
Q1 2021 May 11, 2021	BUY	$26.99 - $40.0 $197,027 - $292,000	7,300 New	7,300 $227,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

Stay updated on New York State Common Retirement Fund with notifications on news.